Data compiled by Redley Lamar · ChainSifter Intelligence
7Suppliers
7Customers
2Debt Items
4Related Chains
Source-Backed Evidence Depth
TransCode Therapeutics, Inc. (RNAZ) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
17Total relationships
3Distinct source URLs
11High confidence
0.786Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
TransCode Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
ABCJ-LLC
ABCJ-LLC
90%
in connection with our acquisition of ABCJ, LLC, the parent company of Polynoma, LLC
POLYNOMA-LLC
POLYNOMA-LLC
90%
in connection with our acquisition of ABCJ, LLC, the parent company of Polynoma, LLC
THE-GENERAL-HOSPITAL-CORPORATION
THE-GENERAL-HOSPITAL-CORPORATION
90%
Exclusive Patent License Agreement by and between TransCode Therapeutics, Inc. and The General Hospital Corporation, d/b/a Massachusetts General Hospital
UNLEASH-IMMUNO-ONCOLYTICS-INC
UNLEASH-IMMUNO-ONCOLYTICS-INC
90%
the issuance of common stock upon the conversion of our Series C Non-Voting Convertible Preferred Stock, par value $0.0001 per share issued pursuant to our licensing agreement with Unleash Immuno Onc…
DEFJ
DEFJ
80%
On October 8, 2025, under the Purchase Agreement, DEFJ agreed to reimburse the C
YA-II-PN-LTD
YA-II-PN-LTD
80%
the potential issuance of shares of common stock pursuant to a Standby Equity Purchase Agreement (the “SEPA”) by and between us and YA II PN, LTD
Reciprocal relationship from CYTOF graph: Reciprocal relationship from RNAZ graph: Reciprocal relationship from CYTOF graph: hnologies There are several companies offering commercial- or developmenta…
TransCode Therapeutics, Inc. Customers
Ticker
Name
Confidence
Evidence
YA-II-PN-LTD
YA-II-PN-LTD
85%
YA II entered into a Standby Equity Purchase Agreement ("SEPA") with the Company dated as of April 6, 2026
DEFJ-LLC
DEFJ-LLC
80%
In connection with our October 2025 acquisition of ABCJ, LLC ("ABCJ") from DEFJ, LLC, ("DEFJ"), DEFJ agreed to reimburse us for up to $3 million of certain expenses
ABCJ-LLC
ABCJ-LLC
62%
terms. Going Concern These consolidated financial statements have been prepared assuming that the Company will continue as a going concern which contemplates the continuation of operations, realizati…
DELAWARE-GENERAL-CORPORATION
DELAWARE-GENERAL-CORPORATION
62%
ecommendation is made, without placing the financial or other interest of the broker, dealer, or natural person who is an associated person of a broker or dealer making the recommendation ahead of th…
NASDAQ-STOCK-MARKET-LLC
NASDAQ-STOCK-MARKET-LLC
62%
n matters for their consideration, including: (i) approval of the conversion of shares of Series A Preferred Stock into shares of Common Stock in accordance with the rules of the Nasdaq Stock Market …
POLYNOMA-LLC
POLYNOMA-LLC
62%
terms. Going Concern These consolidated financial statements have been prepared assuming that the Company will continue as a going concern which contemplates the continuation of operations, realizati…
UNLEASH-IMMUNO-ONCOLYTICS-INC
UNLEASH-IMMUNO-ONCOLYTICS-INC
62%
ination of fair value of the securities issued as consideration, the allocation of consideration to the specific IPR&D programs acquired and the tax implications related to the updates to the purchas…
TransCode Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
RNAZ-DEBT-12244
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2021-12-31.
RNAZ-DEBT-12243
Warrants outstanding: 20
90%
xbrl warrant detail from xbrl 2025-12-31.
TransCode Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for TransCode Therapeutics, Inc..
TransCode Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
RNAZ-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 8 tracked holders.
TransCode Therapeutics, Inc. Extended Supply Chain Network
